Primary antithrombotic prevention with aspirin is not indicated in asymptomatic patients with confirmed antiphospholipid (aPL) positivity without systemic autoimmune disorders because: a) the estimated prevalence of thrombosis in unselected cases is about 1% patientyears (range 0-2.8); b) this level of thrombotic risk is equivalent to that of major bleeding associated with the use of aspirin and therefore the expected benefit does not outweigh the risk; c) these expectations have been confirmed by at least one randomized clinical trial, although with methodological limits. The management of modifiable thrombotic risk factors can be an alternative and safer strategy, considering that many vascular events occur in the presence of concomitant non-aPL triggering conditions. Whether primary prophylaxis with aspirin may be useful for some subsets of aPL patients at particularly high thrombotic risk, such as those with overt systemic autoimmune disorders or with special patterns of antibodies ('triple positivity'), remains to be established. Lupus (2012) 21, 747-750.
The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by: a) the presence of autoantibodies directed against protein/phospholipid complexes (aPL), including lupus anticoagulant (LA), anticardiolipin and anti-beta2 glycoprotein I antibodies; b) clinical symptoms of vascular thrombosis or pregnancy morbidity. 1 Patients with typical APS have a high risk of recurrent thrombosis and should be given appropriate anticoagulation. 2 However, asymptomatic cases carrying only the laboratory criteria for APS are at lower risk of vascular complications and whether they need a primary prophylaxis with low-dose aspirin is a matter of debate. To tackle this issue, the expected benefit/risk of acetylsalicylic acid (ASA) in the prevention of thrombosis and the results of recent clinical studies in this setting should be considered.
Lessons from primary prevention trials with aspirin outside APS
The use of aspirin in seven primary prevention trials enrolling approximately 58,000 persons who were at variable cardiovascular risk has been reviewed. 3, 4 If one evaluates the absolute benefits of aspirin prophylaxis in these trials, it becomes apparent that the level of cardiovascular risk in the control population (i.e. those receiving placebo) is a major determinant of the benefit of antiplatelet therapy (Figure 1 ). In individuals who are at low risk for vascular occlusion (e.g. 1% per year), a very small absolute benefit is offset by exposure of a large number of healthy subjects to undue bleeding complications. In contrast, in patients who are at high risk of cardiovascular or cerebrovascular complications (e.g. >3% per year), the substantial absolute benefit of aspirin prophylaxis clearly outweighs the risk. As a result, the first step in deciding whether to consider aspirin for primary prophylaxis is an assessment of the annual risk for that individual of developing a cardiovascular event.
Estimating the risk of thrombosis in asymptomatic APS patients
Based on a limited number of studies, unselected asymptomatic aPL-positive patients have a 0-2.8% annual thrombosis risk. In a three-year prospective observational cohort study of 178 asymptomatic, persistently aPL-positive individuals without systemic autoimmune diseases, Giron-Gonzalez et al. reported no thromboses in participants receiving no prophylaxis (except during high-risk periods such as surgeries). 5 In another prospective observational cohort study of 194 consecutive patients with aPL, including 47 cases (24%) with SLE, the thrombosis incidence rate in asymptomatic was 11.3% in a follow-up period of almost four years (2.8% annual incidence rate, respectively, assuming linear risk of thrombosis). 6 The Italian Registry of aPL carried out a multicentre, prospective cohort investigation of 360 unselected patients, mostly with LA (>90%), prospectively observed for a median of 3.9 years (range 0.5-5). 7 Overt SLE or SLE-like syndrome was diagnosed in 135 patients (37%). Thirty-four patients developed a thrombotic complication, with a total incidence of 2.5% patient-years. Multivariate logistic regression analysis identified two independent risk factors for thrombotic events: a previous thrombosis (relative risk [RR] 4.9; 95% confidence interval [CI], 1.76-13.7; p < 0.005) and IgG ACA titre above 40 units (RR 3.66; 95% CI, 1.24-10.8; p < 0.01). The incidence of thrombosis in 243 asymptomatic patients (67%) was 0.95% per year.
In a recent prospective study, the APS Study Group of the Italian Society of Rheumatology evaluated incidence and risk factors for a first vascular event in 258 asymptomatic aPL carriers (69% with systemic autoimmune disorders) followed for a mean of 35 months (range 1-48). 8 The annual incidence rate of first thrombosis was 1.86% and hypertension and the presence of LA were identified by multivariate logistic regression analysis as independent risk factors.
The role of associated thrombotic risk factors
The thrombosis risk in the general population rises with the increasing number of risk factors and age. Thus, it is not clear whether aPL is the only risk factor needed for every individual to develop thrombosis. Well-established thrombosis risk factors such as hypertension or smoking can coexist in aPL-positive individuals at the time of an event and may even be responsible for triggering acute thrombosis. Based on retrospective and cross-sectional studies, more than half of the APS patients with vascular events had coexisting non-aPL thrombotic risk factors at the time of their events. 9, 10 The results obtained in aspirin trials that have recruited high-risk males and females clearly demonstrate that proper management of modifiable risk factors by current multifactorial strategies can reduce the actual risk of experiencing a major vascular event to a level at which the additional benefit of aspirin does not clearly outweigh the risk of major bleeding complications. 2 An important issue has been recently raised by Pengo and coworkers in an elegant study of 104 asymptomatic aPL carriers (47% with autoimmune disorders) characterized by an aPL profile considered at high risk for a first vascular event (positive LA, anticardiolipin and anti-beta2 glycoprotein antibodies, so called 'triple positivity'). 11 The incidence of first thrombosis was as high as 5.3% per year, confirming that the aPL profile should be considered as important prognostic information to decide the optimal primary antithrombotic prophylaxis in these patients.
Clinical studies of aspirin in asymptomatic patients with aPL
Primary thrombosis prophylaxis strategies in asymptomatic aPL-positive individuals are poorly studied. A subgroup analysis of the Physicians' Health Study showed that 325 mg aspirin every other day was not protective against DVT or pulmonary embolism in individuals with moderate-tohigh titre aCL. 12 The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicentre, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals (mostly with systemic autoimmune diseases) were randomized to receive a daily dose of 81 mg of aspirin or placebo. 13 In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively. In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean AE SD follow-up period 2.30 AE 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 non-randomized individuals were followed up prospectively (mean AE SD follow-up period 2.46 AE 0.76 years); 61 received aspirin and 13 did not. In the randomized study, the overall thrombosis incidence rate was 1.33 per 100 patient-years; 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% CI 0.69-1.56) (p ¼ 0.83). Similarly, in the observational study, the thrombosis incidence rates were 2.2 per 100 patient-years overall, 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but one patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis. These results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis and develop vascular events when additional thrombosis risk factors are present.
There are some limitations of this study, including the small sample size and insufficient power resulting from the rarity of aPL and the difficulty in identifying asymptomatic aPL-positive patients. Despite these drawbacks, the APLASA study is the first randomized clinical trial of asymptomatic, persistently aPL-positive individuals and its results are consistent with the bulk of epidemiological and clinical data reviewed above.
Conclusions
Aspirin is not indicated in all asymptomatic patients with confirmed aPL positivity because: a) the estimated prevalence of thrombosis in unselected cases is about 1% patient-years (range 0-2.8); b) this level of thrombotic risk is equivalent to that of major bleeding associated with the use of aspirin and therefore the expected benefit does not outweigh the risk (Figure 1) ; c) these expectations have been confirmed by at least one randomized clinical trial, although with methodological limits. 13 The management of modifiable thrombotic risk factors can be an alternative and safer strategy, considering that many vascular events occur in the presence of concomitant non-aPL triggering conditions. Whether primary prophylaxis with aspirin may be useful for some subsets of aPL patients at particularly high thrombotic risk, such as those with overt systemic autoimmune disorders or with special patterns of antibodies ('triple positivity'), 11 remains to be established in appropriate clinical studies.
Funding

